Table 1 Associations between SLC7A11 expression and various clinicopathological features in HCC patients based on TCGA dataset

Gender

Male

252

136(53.97)

116 (46.03)

0.01 < p < 0.05

Female

121

51 (42.15)

70 (57.85)

Age (years)

 < 61

177

84 (47.46)

93 (52.54)

0.05

≧61

195

102 (52.31)

93 (47.69)

Preoperative serum AFP level

Positive

148

82 (55.41)

66 (44.59)

0.01 < p < 0.05

Negative

131

55 (41.98)

76 (58.02)

Tumor Stage (American Joint Committee on Cancer)

T1 ~ T2

277

136 (49.10)

141 (50.90)

0.06

T3 ~ T4

93

51 (54.84)

42 (45.16)

Metastasis Stage (American Joint Committee on Cancer)

M0

267

134(50.19)

133 (49.81)

0.25

M1

4

1 (25.00)

3 (75.00)

Lymph Node Stage (American Joint Committee on Cancer)

N0

253

128(50.59)

125 (49.41)

0.26

N1

4

3 (75.00)

1 (25.00)

Disease Free Status

Non- Recurred

146

65 (44.52)

81 (55.48)

0.05

Recurred

176

89 (50.57)

87 (49.43)

Overall Survival Status

Living

243

110 (45.27)

133 (54.73)

0.01 < p < 0.05

Deceased

130

77 (59.23)

53 (40.77)

Hepatic Fibrosis Ishak Score

0

75

35(46.67)

40(53.33)

0.12

1 ~ 4

59

30(50.85)

29(49.15)

5 ~ 6

80

38(47.50)

42 (52.50)

Neoplasm Disease Stage (American Joint Committee on Cancer)

Stage I

172

80(46.51)

92(53.49)

 > 0.05

Stage II

87

48(55.17)

39(44.83)

Stage III

85

49(57.65)

38(44.71)

Stage IV

5

2(40.00)

3(60.00)

Neoplasm Histologic Grade

G1

55

20(36.36)

35(63.64)

 > 0.05

G2

178

89(50.00)

89(50.00)

G3

123

71(57.72)

52(42.28)

G4

12

7(58.33)

5(41.67)

Vascular Invasion

None

207

96(46.38)

111(53.62)

0.05

Micro

110

58(52.73)

52(47.27)

Adjacent Hepatic Tissue Inflammation Extent

None

118

53(44.92)

65(55.08)

 > 0.05

Mild

100

49(49.00)

51(51.00)

Severe

18

8(44.44)

10(55.56)

Surgical Margin Resection Status

R0

326

158(48.47)

168(51.53)

 > 0.05

R1

17

10(58.82)

7(41.18)

R2

1

0(0.00)

1(100.00)